These IO drugs have revolutionized the treatment of certain cancers (e.g. melanoma). Are there similar potential “black swan events“ awaiting psychiatric therapeutics? We will mention only two possibilities here. The first is the potential of developing large molecule therapeutics, such as ...
San Francisco-based Insitro announced today that it has entered a five-year discovery collaboration agreement with Bristol Myers Squibb to discover and develop novel therapies for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Through this collaboration, ...
New opportunities for treatment of neurodegenerative disease through the modulation of TDP-43Alzheimer's disease (AD)Amyotrophic lateral sclerosis (ALS)Cytoplasmic aggregatesFrontotemporal dementia (FTD)Pharmacological interventions and drug discoveryRandomized clinical trial (RCT)...
In almost half of the cases with bvFTD, the damage to the neurons in the brain is caused by the build-up of a protein called tau. This protein is a major target for research in the prevention and treatment of Alzheimer’s and other dementias, as a way to reverse the neurodegeneration ...
It may also hold opportunities for treating more common forms of dementia, such as Alzheimer’s disease, which is the second most common cause of death in Australia after heart disease. The new treatment, dubbed CTx1000, targets pathological build-ups of the protein TDP-43 in cel...
Testosterone may hold therapeutic promise for the treatment of ischemic stroke in aging: a closer look at laboratory findings. Adv Pharm Bull. 2019;9:48–55. PubMed CAS Google Scholar Yang C, Hawkins KE, Dore S, Candelario-Jalil E. Neuroinflammatory mechanisms of blood-brain barrier damage ...
Researchers discovered a crucial protein, TAF15, in frontotemporal dementia (FTD) cases. This finding, offering new treatment avenues, was achieved using advanced neuropathologic and molecular techniques, marking a breakthrough in understanding and potentially treating this form of dementia. ...
Also, AZP2006 binds to PSAP (the cofactor of PGRN) and inhibits TLR9 receptors normally responsible for proinflammation when activated. Altogether, these results showed the high potential of AZP2006 as a new putative treatment for AD and related diseases. Alzheimer's disease (AD) is the most...
Interleukin 17A (IL-17A) –It is now generally accepted that IL-17A causes disease via the activation of microglial cells and can be used effectively in the diagnosis and treatment monitoring of human autoimmune diseases and neurodegenerative diseases such as AD, PD, MS, and ALS.15 ...
Interventions that reduce local protein concentrations might ameliorate diffusive protein spread for many diseases. Hypothesis Profiles of network disintegration provide biomarkers for tracking disease evolution and treatment response. Key experiments Detailed natural history studies and incorporation of network-...